Ariad Pharmaceuticals (NASDAQ: ARIA) $7 Biotech Stock Could Easily Double Again From Here

What a way to start 2014! Gloom and doom have struck the stock market with a roughly 1,000-point decline in the Dow Jones Industrial Average.

The Federal Reserve's dialing back of its massive bond buying program, emerging market weakness and several economic indicators turning downward are some of the culprits of the heavy selling in the first month of the year.

While many supposed stock market experts and perma-bears are claiming that the selling is signaling much more downside to come, I wholeheartedly disagree. This selling is nothing more than simple profit-taking after the incredible bull market of 2013.

One very practical reason is that investors wanted to delay paying taxes on their capital gains. This caused many to wait until 2014 to take profits.  (more)

Please share this article